Exploring the potency of polyphenol-rich blend from Lonicera caerulea var. Kamtschatica sevast., Aronia melanocarpa, and Echinacea purpurea: Promising anti-inflammatory, antioxidant, and antiviral properties

• Published in: Heliyon Vol. 10; no. 15; p. e35630
• Main Authors: Zima, Katarzyna, Khaidakov, Barbara, Sochocka, Marta, Ochnik, Michał, Lemke, Krzysztof, Kowalczyk, Paulina
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 15.08.2024; Elsevier
• Subjects: Antioxidant; Antiviral activity; Immunomodulation; Plant extracts; Polyphenol; TPC; HRP; MTT; TCID50; LPS; LDH; Polyphenol; RBD; SI; Antiviral activity; AVAs; HCoV‐OC43; CTEs; IL; TBP; CC50; Immunomodulation; TMB; SOD; EP; Antioxidant; AM; Plant extracts; ACE2; TNF-α; LCK; URTI; IPA; GAPDH
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e35630

Previous studies have highlighted the beneficial properties of plants rich in polyphenols, such as Lonicera caerulea var. Kamtschatica Sevast. (LCK), Aronia melanocarpa (AM), and Echinacea purpurea (EP). These plants have demonstrated antioxidant, immunomodulatory, and potential antiviral effects. Thus, the objective of this study was to investigate the impact of the ELA blend, a polyphenol-rich blend containing EP, LCK, and AM, on the cellular mechanisms involved in viral infection. To assess the effects of the ELA blend, various experiments were conducted using A549 cells and a mucociliary tissue 3D model called EpiAirway™. Inflammation and oxidative stress induced by LPS were evaluated through measurements of SOD activity, ELISA, and qPCR analysis. Additionally, antiviral assays were performed in a cell-present environment to examine the blend's effectiveness against HCoV-OC43. The results showed that the ELA blend-treated group exhibited reduced expression of IL1B, CXCL8, ICAM1, MCP1, and RELA in both A549 cells and EpiAirway™. Moreover, the blend enhanced the expression of CAT, HMOX1, SOD1, and SOD2 in A549 cells. The antiviral activity of the ELA blend was also investigated, i.e. its influence on viral replication cycle, to determine the potential as an antiviral preparation. At the highest non-cytotoxic concentration, the ELA blend demonstrated a 87.5 % reduction in viral titer when administered simultaneously with HCoV-OC43. It emphasize potential ability of the preparation to block viral entry to the host cells. At the same time, ELA blend did not express virucidal activity, i.e. inactivation of free viral particles, against HCoV-OC43. In conclusion, ELA blend displayed antiviral activity and exhibited immunomodulatory and antioxidant effects. Based on these findings, it can be concluded that ELA blend has potential for the prevention and treatment of viral infections.